Hepion Pharmaceuticals Stock Analysis
HEPA Stock | USD 0.67 0.03 4.69% |
Hepion Pharmaceuticals is undervalued with Real Value of 6.4 and Target Price of 23.67. The main objective of Hepion Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Hepion Pharmaceuticals is worth, separate from its market price. There are two main types of Hepion Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Hepion Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Hepion Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Hepion |
Hepion Stock Analysis Notes
The book value of the company was currently reported as 1.16. The company recorded a loss per share of 4.4. Hepion Pharmaceuticals last dividend was issued on the 3rd of June 2019. The entity had 1:20 split on the 11th of May 2023. Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. Hepion Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To learn more about Hepion Pharmaceuticals call BSc BSc at 732 902 4000 or check out https://hepionpharma.com.Hepion Pharmaceuticals Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Hepion Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Hepion Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Hepion Pharmaceuticals generated a negative expected return over the last 90 days | |
Hepion Pharmaceuticals has high historical volatility and very poor performance | |
Hepion Pharmaceuticals has some characteristics of a very speculative penny stock | |
Hepion Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (48.93 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Hepion Pharmaceuticals currently holds about 59.15 M in cash with (40.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Hepion Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Latest headline from investing.com: Hepion Pharmaceuticals faces Nasdaq delisting risk |
Hepion Pharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Hepion Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
19th of February 2024 Upcoming Quarterly Report | View | |
10th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
19th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Hepion Largest EPS Surprises
Earnings surprises can significantly impact Hepion Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-05-16 | 2022-03-31 | -0.13 | -0.09 | 0.04 | 30 | ||
2022-11-14 | 2022-09-30 | -0.17 | -0.11 | 0.06 | 35 | ||
2021-11-15 | 2021-09-30 | -0.19 | -0.12 | 0.07 | 36 |
Hepion Stock Institutional Investors
Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.7 K | Federation Des Caisses Desjardins Du Quebec | 2024-06-30 | 175 | Advisor Group Holdings, Inc. | 2024-06-30 | 113 | Macquarie Group Ltd | 2024-06-30 | 88.0 | Group One Trading, Lp | 2024-06-30 | 84.0 | Ubs Group Ag | 2024-06-30 | 70.0 | Advisornet Financial, Inc | 2024-09-30 | 63.0 | Bank Of America Corp | 2024-06-30 | 46.0 | Barclays Plc | 2024-06-30 | 16.0 | Anson Funds Management Lp | 2024-09-30 | 231.8 K | Vanguard Group Inc | 2024-09-30 | 90.9 K |
Hepion Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.65 M.Hepion Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (2.70) | (2.84) | |
Return On Capital Employed | (3.78) | (3.59) | |
Return On Assets | (2.70) | (2.84) | |
Return On Equity | (6.72) | (6.38) |
Management Efficiency
Hepion Pharmaceuticals has return on total asset (ROA) of (0.9282) % which means that it has lost $0.9282 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8952) %, meaning that it created substantial loss on money invested by shareholders. Hepion Pharmaceuticals' management efficiency ratios could be used to measure how well Hepion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -2.84. The current year's Return On Capital Employed is expected to grow to -3.59. At present, Hepion Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 24 M, whereas Non Currrent Assets Other are forecasted to decline to about 228.6 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 1.83 | 1.74 | |
Tangible Book Value Per Share | 1.83 | 1.93 | |
Enterprise Value Over EBITDA | 0.03 | 0.04 | |
Price Book Value Ratio | 1.77 | 1.86 | |
Enterprise Value Multiple | 0.03 | 0.04 | |
Price Fair Value | 1.77 | 1.86 | |
Enterprise Value | -2 M | -2.1 M |
Effective leadership at Hepion Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 1.813 | Return On Assets (0.93) | Return On Equity (1.90) |
Technical Drivers
As of the 1st of December, Hepion Pharmaceuticals retains the Standard Deviation of 5.47, market risk adjusted performance of (0.08), and Risk Adjusted Performance of (0.01). Hepion Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Hepion Pharmaceuticals Price Movement Analysis
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Hepion Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Hepion Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Hepion Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hepion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hepion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hepion Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hepion Pharmaceuticals Outstanding Bonds
Hepion Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Hepion Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Hepion bonds can be classified according to their maturity, which is the date when Hepion Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Hepion Pharmaceuticals Predictive Daily Indicators
Hepion Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Hepion Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Hepion Pharmaceuticals Forecast Models
Hepion Pharmaceuticals' time-series forecasting models are one of many Hepion Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hepion Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Hepion Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Hepion Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Hepion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Hepion Pharmaceuticals. By using and applying Hepion Stock analysis, traders can create a robust methodology for identifying Hepion entry and exit points for their positions.
Last Reported | Projected for Next Year |
Current Hepion Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Hepion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Hepion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
23.67 | Hold | 1 | Odds |
Most Hepion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Hepion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Hepion Pharmaceuticals, talking to its executives and customers, or listening to Hepion conference calls.
Hepion Stock Analysis Indicators
Hepion Pharmaceuticals stock analysis indicators help investors evaluate how Hepion Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Hepion Pharmaceuticals shares will generate the highest return on investment. By understating and applying Hepion Pharmaceuticals stock analysis, traders can identify Hepion Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow | 51.2 M | |
Total Stockholder Equity | 7.3 M | |
Capital Lease Obligations | 209 K | |
Property Plant And Equipment Net | 242.4 K | |
Cash And Short Term Investments | 14.8 M | |
Net Invested Capital | 5.6 M | |
Cash | 14.8 M | |
50 Day M A | 0.6623 | |
Net Interest Income | -9566.00 | |
Total Current Liabilities | 5.3 M | |
Investments | -30.3 K | |
Interest Expense | 9465.00 | |
Stock Based Compensation | 1.3 M | |
Common Stock Shares Outstanding | 4 M | |
Tax Provision | -2.9 M | |
Free Cash Flow | -40.9 M | |
Operating Income | -48.4 M | |
Other Current Assets | 2.7 M | |
Accounts Payable | 2.3 M | |
Net Debt | -14.6 M | |
Depreciation | 67.1 K | |
Other Operating Expenses | 48.4 M | |
Non Current Assets Total | 606.6 K | |
Liabilities And Stockholders Equity | 18.1 M | |
Home Category | Domestic | |
Non Currrent Assets Other | 364.2 K |
Complementary Tools for Hepion Stock analysis
When running Hepion Pharmaceuticals' price analysis, check to measure Hepion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hepion Pharmaceuticals is operating at the current time. Most of Hepion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hepion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hepion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hepion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |